

MYOBLOC is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.

Important Safety Information for MYOBLOC

MYOBLOC has a boxed warning related to the distant spread of toxin effect: The effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have occurred at doses comparable to those used to treat cervical dystonia and at lower doses.

The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. The vast majority of these adverse events were mild to moderate, temporary, self-resolving, and more common with higher doses. These adverse events may occur within the first week following treatment and may have a duration of several months. In controlled clinical trials, few patients (<1%) stopped treatment due to dry mouth or dysphagia. There is a reduced frequency of dry mouth and dysphagia reported with continued treatment. Dysphagia has commonly been reported by patients treated with all botulinum toxins for cervical dystonia.

Caution should be exercised when administering MYOBLOC to individuals with motor neuron disease (eg, amyotrophic lateral sclerosis), peripheral motor neuropathic diseases (eg, motor neuropathy) or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome). These patients may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC. In these patients, rare cases of dysphagia severe enough to cause aspiration pneumonia or to warrant the insertion of a gastric feeding tube have also been reported.

Coadministration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.



MYOBLOC®
rimabotulinumtoxinB
Injection [5,000 Units/mL]

For more information about our Reimbursement Services and Patient Assistance Programs, or to obtain application forms, please call **1-888-461-2255, option 3** or visit our Web site at www.myobloc-reimbursement.com

SOLSTICE®
NEUROSCIENCES
A US WORLDMEDS COMPANY

MYOBLOC is a registered trademark of Solstice Neurosciences, LLC, a wholly-owned subsidiary of US WorldMeds, LLC.
© 2011 US WorldMeds, LLC USWM-MYO502-1211

Reimbursement Support Program



MYOBLOC®
rimabotulinumtoxinB
Injection [5,000 Units/mL]

Service & Support

1-888-461-2255

9:00 AM - 6:00 PM Eastern Time Monday-Friday
www.myobloc-reimbursement.com

Please see Important Safety Information inside and accompanying full Prescribing Information and Medication Guide.

SOLSTICE®
NEUROSCIENCES
A US WORLDMEDS COMPANY

Reimbursement Services^a for MYOBLOC

Our reimbursement services team uses a case management approach to facilitate the reimbursement process for you and your staff. Our staff is available Monday-Friday, 9:00 AM to 6:00 PM Eastern Time.

- Toll-free Live-answer service: 1-888-461-2255, Option 3
- Toll-free Fax number: 1-888-343-3275

Our staff will assist you in the following areas:

Insurance Verification

We will:

- Provide an in-depth review of coverage which includes *Coverage Alerts and Action Steps*
- Verify patient insurance eligibility
- Check medical and pharmacy benefits
- Clarify copayments and deductibles

Prior Authorization

We will:

- Identify prior authorization requirements
- Facilitate the prior authorization process
- Provide a letter of medical necessity template upon your request
- Provide support to access of clinical information that may be needed for claims upon your written request
- Confirm and validate process activities

Denials and Appeals

We will:

- Research reason(s) for denied claims or prior authorizations
- Facilitate appeal process
- Provide an appeal letter template upon your request

MYOBLOC Billing and Coding Information

Upon your written request, we will provide information on:

- General billing and coding for MYOBLOC
- J-Codes, ICD-9-CM^b, CPT^c and EMG codes
- Accurate claim filing
- Medicare Local Coverage Determinations (LCDs)
- Contact information for carriers and health plans

Online Access to Services

Visit www.myobloc-reimbursement.com for:

- Quick enrollment process
- Easy Case Submission
- Case Status update
- Benefit Investigation results
- Ordering drug for next-day delivery
- Order History
- Hassle-free retreatment submittal

Co-Pay Assistance Program

The Co-Pay Assistance Program assists eligible patients with actual out-of-pocket treatment costs (i.e., drug co-pay cost) for MYOBLOC[®] (rimabotulinumtoxinB) Injection.

Program Benefits*

- Simplified patient application process
- Easy implementation
- Financial assistance to patients for the FDA-approved indication (excludes Medicare, Medicaid, FEP, TRICARE[®], and Massachusetts' residents)
- Active Co-Pay Assistance support

*Available if patient meets eligibility criteria for program

Solstice sets the criteria for the Co-Pay Assistance Program.

To obtain enrollment forms for these programs, please contact us at
1-888-461-2255, option 3 or visit our Web site at
www.myobloc-reimbursement.com

Patient Assistance Program (PAP)

Solstice Neurosciences, LLC is dedicated to supporting the use of MYOBLOC[®] (rimabotulinumtoxinB) Injection for patients who are subject to financial hardship and who have a diagnosis for cervical dystonia as determined by medical professionals.

Solstice sets the criteria for the Patient Assistance Program.

MYOBLOC is available at no charge for patients who:

- Are uninsured
- Are not covered by alternate sources of funding
- Meet specific clinical criteria established by Solstice
- Meet specific Federal Poverty Level guidelines

Solstice Neurosciences, LLC sets the criteria for the Patient Assistance Program (PAP). Acceptance into the program at any time is not a guarantee that patients are entitled to receive assistance indefinitely.

Solstice Neurosciences, LLC reserves the right at any time, and without notice: to modify any reimbursement forms; to modify or discontinue any or all of the aspects of the Program; or to terminate assistance under the Program at any time.

^a Reimbursement services are available only for those patients being treated with MYOBLOC[®] (rimabotulinumtoxinB) Injection for a therapeutic condition for which there is a reasonable expectation for reimbursement from a third-party payer. Physicians are responsible for identifying the clinical indication(s) and documenting medical necessity for any use of MYOBLOC. Questions regarding the clinical use of MYOBLOC should be directed to 1-888-461-2255.

^b ICD-9-CM codes are based on the World Health Organization (WHO) International Classification of Diseases, 9th edition. Solstice Neurosciences, LLC assumes no liability for information contained herein. Solstice Neurosciences, LLC claims no ownership or other interest in the ICD-9-CM codes.

^c CPT[®] codes are copyrighted property of the American Medical Association (AMA). Solstice Neurosciences, LLC assumes no liability for any of the information contained herein. Solstice Neurosciences, LLC claims no ownership or other interest in the CPT codes. CPT codes are provided herein for reference only and are not intended to convey any endorsement or sponsorship by, or affiliation with, the AMA.